Theradiag, a specialist in in vitro diagnostics, was up over 2% on the Paris Bourse on Monday, following the publication of first-half results showing a strong improvement in profitability.

The specialist in "theranostics", a discipline at the interface between treatment and diagnostics, posted a "record" operating profit of 835,000 euros for the first six months of the year, representing an operating margin of 12.5%.

The group, whose tests are used to measure the efficacy of biotherapies in the treatment of chronic diseases, explained that it had benefited from optimized management of its operating expenses, mainly due to the discontinuation of activities in the United States.

Half-year sales came to 6.7 million euros, up 7% from 6.3 million euros in the first half of 2022.

At June 30, net free cash stood at 5.7 million euros, up on the end of March and ahead of the company's business plan.

Copyright (c) 2023 CercleFinance.com. All rights reserved.